Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Conditions in the Tumor Microenvironment Change Role of p53

By LabMedica International staff writers
Posted on 09 Aug 2018
Cancer researchers have found that changes occurring in the tumor microenvironment manipulate the activity of fibroblast p53 protein, causing it to promote rather than restrict cancer growth.

Cancer cells coexist with noncancerous adjacent cells that constitute the tumor microenvironment and impact tumor growth through diverse mechanisms. More...
In particular, cancer-associated fibroblasts (CAFs) promote tumor progression in multiple ways. Earlier studies have revealed that in in contrast to the situation in CAFs, p53 in normal fibroblasts (NFs) plays a tumor-suppressive role to restrict tumor growth.

Investigators at the Weizmann Institute of Science (Rehovot, Israel) set out to study the role of p53 in CAFs. To carry out this research, they used a combination of cell culture and a cancer-carrying mouse model.

The investigators reported in the June 19, 2018, issue of the journal Proceedings of the National Academy of Sciences of the United States of America that the transcriptional program supported by p53 was altered substantially in CAFs relative to NFs. In agreement, the secretion of proteins dependent on p53 was also altered in CAFs. This transcriptional rewiring rendered p53 a significant contributor to the distinct intrinsic features of CAFs, as well as promoted tumor cell migration and invasion in culture.

The ability of CAFs to promote tumor growth in mice was greatly compromised by depletion of their endogenous p53. Furthermore, co-cultivation of NFs with cancer cells partially rendered their p53-dependent transcriptome to be more similar to that of CAFs.

The investigators concluded by saying, "Our findings raise the intriguing possibility that tumor progression may entail a nonmutational conversion (“education”) of stromal p53, from tumor suppressive to tumor supportive."

Related Links:
Weizmann Institute of Science


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Human Estradiol Assay
Human Estradiol CLIA Kit
New
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.